Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts. https://t.co/tsKuLZw7dQ